Investor Group Discloses 11% Stake in Hepion Pharmaceuticals After $500K Private Placement
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
An investor group led by Darin Feinstein has taken an 11% stake in Hepion Pharmaceuticals through a $500,000 private placement, adding to the company's recent capital raises as it battles going concern risks.
Key Events · Ownership and Investor Activity · CTRVP
-
New 11% Stake Acquired
Black Global 5 LLC purchased 10 million shares of common stock for $500,000, representing 11.08% of Hepion's outstanding shares.
-
Warrant for Additional Shares
The deal includes a warrant to buy up to 10 million more shares at $0.06 per share, potentially doubling the stake if exercised.
-
Affiliated Entities Deemed Beneficial Owners
Red Global 3, LLC and Darin Feinstein are deemed beneficial owners of the shares due to their control over Black Global, though they did not directly purchase the securities.
-
Financing Amid Going Concern Doubts
This investment follows a $3.06 million private placement at $0.05 per share on August 4, 2026, as Hepion continues to raise capital to address substantial doubt about its ability to continue as a going concern.
Analysis · CTRVP · Life Sciences
Black Global 5 LLC, along with affiliated entities Red Global 3 and Darin Feinstein, acquired 10 million shares of Hepion Pharmaceuticals for $500,000 in a private placement, giving them an 11.08% stake. The purchase includes a warrant for another 10 million shares at $0.06 each. This investment comes just days after Hepion raised $3.06 million at $0.05 per share, signaling continued reliance on dilutive financing to sustain operations amid going concern doubts.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.